This Friday, the U.S. House will vote on the 21st Century Cures Act.
The Act creates a cohesive, efficient, effective, and patient-centered path to cures.
The 21st Century Cures Act, a substantial piece of legislation that touches on all aspects of medical innovation – from basic research to regulation, from biomarkers to patient data – was spearheaded by House Energy and Commerce Committee Chairman Fred Upton (R-MI) and Oversight and Investigations Subcommittee Ranking Member Diana DeGette (D-CO).
There are many exciting opportunities this bill creates to improve the systems that serve patients. Below are a few of the bill’s most promising measures.
Investment in Critical Science & Research
The National Institutes of Health (NIH) (Section 2)
- The National Institutes of Health has lost almost 25% of its purchasing power over the last ten years, severely limiting basic research. This bill will increase NIH funding by $8.75 billion over the next-five years, bolstering America’s investment in medical innovation.
The U.S. Food & Drug Administration (FDA) (Section 2)
- To ensure the execution of its many exciting new tools and programs to enhance patient input and the scientific capacity of the FDA, the bill increases FDA funding by $550 million over 5 years.
High Risk, High-Reward Research (Section 1028)
- When budgets are tight, researchers are sometimes limited to cautious projects. The bill will ensure that funding exists for high risk research with the potential to lead to medical breakthroughs.
Supporting Young Scientists (Title I Subtitle C)
- NIH will improve its loan repayment programs and develop new programs to ensure that opportunities are being extended to a new generation of elite researchers.
Building a Framework to Better Involve and Incorporate Patients Throughout the Drug Development Process
Putting Patients at the Center of Drug Development (Section 2001)
- This provision creates a series of new steps that operationalize the incorporation of direct patient feedback and assist advocacy organizations, medical researchers, FDA, and industry to realign drug development programs with this important information.
Strengthening the FDA: Streamlining Clinical Trials, Improving Efficiency, and Laying the Groundwork for the Future
Precision Medicine: Biomarker Qualification (2021, Title II Subtitle B)
- The 21st Century Cures Act will create a process by which the FDA could work with researchers and drug developers to qualify new biomarkers, allowing future researchers to measure drug activity and safety more efficiently.
Accelerated Approval Development Plans (Section 2022)
- Accelerated Approval Development Plans will be established to help FDA and drug sponsors to better plan and predict the use of Accelerated Approval.
Streamlined Data Review (Section 2063)
- Supplemental new drug applications (sNDA) are submitted to FDA to expand the safe and effective use of a drug beyond its original setting.The 21st Century Cures Act will expedite this process for drugs that are already well understood, saving time and resources.
Approval of Drugs for Limited Patient Populations (Section 2121)
- FDA will be empowered to offer experimental drugs approval for narrow patient populations, expanding options for patients without established alternatives.
Priority Review for Breakthrough Devices (Section 2201)
- Medical devices that more effectively treat or diagnose serious or life-threatening diseases will benefit from a new, more efficient FDA review pathway.
Keeping and Recruiting the Best & Brightest to FDA (Section 2281)
- As FDA’s responsibilities have grown, it has often found it difficult to hire and retain qualified employees. This bill will better enable FDA to pursue and retain top talent.
A full copy of the House passed The 21st Century Cures Act is available here.
(Links and post updated Sept. 23, 2015)